News

Posted: 2010-01-25

VANCOUVER, BRITISH COLUMBIA – The Vancouver Prostate Centre announced today an extended collaboration with AstraZeneca that sees the Vancouver Prostate Centre receive $700,000 over two years towards research that targets treatment-resistant prostate cancer.

The research, which is being coordinated through the Vancouver Prostate Centre ― a Centre of Excellence for Commercialization and Research ― evaluates AstraZeneca's androgen receptor-targeting small molecules, as well as, molecules that target cell cycle growth to slow, or stop, tumour proliferation in prostate cancer.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Dr. Flannigan
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi